Ameloblastoma Cell Models for Research

Ameloblastoma is a rare, benign but locally aggressive odontogenic tumor of the jaw, accounting for approximately 1% of all oral tumors and 10% of odontogenic tumors (WHO Classification of Head and Neck Tumours, 4th edition, 2017). The global incidence is estimated at 0.5–1.0 cases per million person-years, with no significant sex predilection and a peak age of 30–40 years (WHO). Although benign, it has a high recurrence rate of 15–25% after surgical resection, and rare malignant transformation can occur, leading to metastasis (NCI SEER data). The 5-year survival for localized ameloblastoma is >95%, but for metastatic cases it drops to <50% (NCI). Key risk factors include impacted teeth, dental infections, and genetic predisposition, though no definitive environmental cause is established. The disease's impact is significant due to facial disfigurement, functional impairment, and the need for extensive surgery.

Ameloblastoma is an ideal model for studying oncogenic signaling in rare tumors, particularly the MAPK pathway, due to its high frequency of BRAF and RAS mutations. It provides a unique opportunity to investigate tumorigenesis in odontogenic epithelium, which shares features with both epithelial and mesenchymal tissues. Public datasets, including TCGA (though limited) and COSMIC, provide mutation profiles. Open questions include the role of Hedgehog signaling, the mechanisms of local invasion, and the development of targeted therapies. Gene-edited cell models are crucial for functional validation of these mutations and for drug screening, as primary cultures are difficult to maintain.

The pathogenesis of ameloblastoma is driven by several key pathways:

1. MAPK/ERK Pathway – Constitutive activation via BRAF or RAS mutations promotes cell proliferation and survival.

2. Hedgehog (HH) Signaling – Aberrant activation of SMO and GLI transcription factors contributes to tumor growth and invasion.

3. Wnt/β-catenin Pathway – Mutations in CTNNB1 or APC lead to nuclear β-catenin accumulation, enhancing epithelial-mesenchymal transition.

4. PI3K/AKT/mTOR Pathway – Activation through PTEN loss or PIK3CA mutations supports cell growth and resistance to apoptosis.

These pathways often interact, creating a complex network that can be targeted by combination therapies.

Data compiled from COSMIC and TCGA (PanCancer Atlas) and published studies (e.g., Brown et al., 2014; Kurppa et al., 2014).

Key deregulated networks in ameloblastoma include:

• • MAPK/ERK cascade: BRAF V600E activates MEK1/2 and ERK1/2, leading to transcription of proliferation genes (e.g., CCND1, MYC).
• • Hedgehog signaling: SMO mutations lead to GLI1/2 nuclear translocation, upregulating target genes like PTCH1 and BCL2.
• • Wnt/β-catenin pathway: Nuclear β-catenin activates TCF/LEF transcription factors, promoting EMT and invasion.
• • PI3K/AKT/mTOR: PTEN loss or PIK3CA mutations activate AKT, inhibiting apoptosis and enhancing cell cycle progression.
• • Apoptosis evasion: Overexpression of BCL2 and survivin, often downstream of MAPK and HH, blocks programmed cell death.

These networks provide multiple therapeutic targets, including BRAF inhibitors (vemurafenib), MEK inhibitors (trametinib), and SMO antagonists (vismodegib).

Organoid cultures derived from patient tumors retain the histological and genetic features of the original tumor, including BRAF mutations, and are valuable for drug testing. They can be established from surgical specimens and maintain 3D architecture, allowing for more physiologically relevant studies than 2D monolayers.

• • Patient-Derived Xenografts (PDX): Implantation of human ameloblastoma tissue into immunodeficient mice (e.g., NSG) preserves tumor heterogeneity and is used for drug efficacy studies.
• • Genetically Engineered Mouse Models (GEMM): Conditional expression of BRAF V600E in odontogenic epithelium (e.g., using K14-Cre) recapitulates ameloblastoma-like lesions, enabling study of tumor initiation and progression.
• • Induced Models: Chemical carcinogenesis (e.g., 4-nitroquinoline-1-oxide) in rodents induces oral tumors, but not specifically ameloblastoma, limiting their use.

These models are essential for preclinical validation of targeted therapies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations found in ameloblastoma. For example:

• • BRAF V600E knock-in in AM-1 cells to study MAPK pathway activation.
• • KRAS G12D knock-in in wild-type cells to model RAS-driven tumorigenesis.
• • TP53 knockout to investigate tumor suppressor loss in malignant transformation.
• • SMO L412F knock-in to activate Hedgehog signaling.

These models are sequence-verified and can be generated with or without reporter tags (e.g., GFP, luciferase) for in vivo imaging. Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent, reproducible models, but they are also available from commercial sources. They are ideal for drug screening, target validation, and functional genomics.

Knockout and knock-in lines are used to validate the functional role of genes in ameloblastoma. For example:

• • BRAF V600E knock-in in AM-1 cells increases ERK phosphorylation and cell proliferation, confirming its oncogenic role.
• • TP53 knockout in AM-3 cells enhances genomic instability and resistance to apoptosis.
• • SMO knockout reduces cell viability and colony formation, demonstrating dependency on Hedgehog signaling.

These models allow for loss-of-function and gain-of-function studies, providing direct evidence of gene function.

Isogenic pairs (e.g., BRAF V600E vs. wild-type) are used to screen for selective inhibitors. For instance:

• • Vemurafenib (BRAF inhibitor) shows selective cytotoxicity in BRAF V600E knock-in cells, while wild-type cells are resistant.
• • Trametinib (MEK inhibitor) is effective in KRAS mutant lines, but resistance can emerge via PI3K pathway activation.

Gene-edited models can be used to study resistance mechanisms by exposing cells to increasing drug concentrations and identifying secondary mutations.

CRISPR synthetic lethality screens can identify genes that are essential only in the presence of specific mutations. For example:

• • In BRAF V600E cells, knocking out genes like DUSP6 (a negative regulator of ERK) may be lethal, revealing potential therapeutic targets.
• • In PTEN-null cells, targeting PI3K isoforms (e.g., p110β) may be synthetically lethal.

These screens, combined with gene-edited models, accelerate the discovery of novel biomarkers and drug targets.